hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
By the middle of 1982, the Soviet Union alone maintained major mycological herbaria across 25 research institutions or museums and 11 universities, academies, and institutes, together preserving more than one million fungal specimens, including over 5,000 type specimens. The transition from morphology-based systematics to phylogenetics in the 1980s and 1990s further changed the role of historical collections, as scientists began extracting DNA from specimens collected more than a century earlier. Historical plant herbaria as well as dedicated mycological collections have also yielded valuable fungal and oomycete records when older specimens were re-examined for disease symptoms that were not the original focus of collection.
In chemistry, the molar mass (M) (sometimes called molecular weight or formula weight, but see related quantities for usage) of a chemical substance (element or compound) is defined as the ratio between the mass (m) and the amount of substance (n, measured in moles) of any sample of the substance: M = m/n. The molar mass is a bulk, not molecular, property of a substance. The molar mass is a weighted average of many instances of the element or compound, which often vary in mass due to the presence of isotopes. Most commonly, the molar mass is computed from the standard atomic weights and is thus a terrestrial average and a function of the relative abundance of the isotopes of the constituent atoms on Earth. The molecular mass (for molecular compounds) and formula mass (for non-molecular compounds, such as ionic salts) are commonly used as synonyms of molar mass, as the numerical values are identical (for all practical purposes), differing only in units (dalton vs. g/mol or kg/kmol). However, the most authoritative sources define it differently. The difference is that molecular mass is the mass of one specific particle or molecule (a microscopic quantity), while the molar mass is an average over many particles or molecules (a macroscopic quantity). The molar mass is an intensive property of the substance, that does not depend on the size of the sample. In the International System of Units (SI), the coherent unit of molar mass is kg/mol. However, for historical reasons, molar masses are almost always expressed with the unit g/mol (or equivalently in kg/kmol).
This work led to the first successful sequence-based analysis of the genomes of single cancer cells from tumors by Wigler's then-graduate student Nick Navin, and subsequently, tumor cells in circulation by Wigler's collaborator Jim Hicks. In the early 2000s, Wigler, Jonathan Sebat and Lakshmi Muthuswamy began copy number analysis of healthy individuals, leading to the discovery of a new source of genetic variability, copy number variations or CNVs. The abundance of CNVs in the human genome is a major source of individual variation. The team at CSHL then continued this line of work to demonstrate that spontaneous germ-line mutation is likely to be a major cause for autism. Their observations and theories about autism provide a now widely accepted approach for understanding other human mental and physical abnormalities.
=== Hydrogen Isotope Analysis === Hydrogen isotope analysis is used to help reconstruct environmental change. Dinosterol is a particularly good target for such analysis because it is commonly found in high concentrations in a variety of aquatic environments and is well preserved in the sediment record. Hydrogen isotope analysis requires a purification method that achieves GC baseline resolution and is high yielding. Dinosterol coelutes with other sterols during GC; therefore a procedure for proper purification that involves reversed phase-high performance liquid chromatography (RP-HPLC) was developed by Atwood et al. The hydrogen isotope ratios in dinosterol can be used to reconstruct salinity semi-quantitatively. In a study by Schwab et al., the hydrogen isotope ratio of dinosterol was measured in suspended particles and surface sediments from the Chesapeake Bay estuary. The D/H ratio was found to decrease by 0.99 ± 0.23% per unit increase in salinity over the salinity range 10–29 PSU. The correlation between hydrogen isotopic response and salinity may result from diminished exchange of water between algal cells and their environment, lower growth rates and/or increased production of osmolytes at high salinities.
Sources: en.wikipedia.org
Omics.org Archived 2014-01-02 at the Wayback Machine Omics terms and concepts home page. Probably the first omics web page created. List of omics Archived 2015-07-09 at the Wayback Machine, including references/origins. Maintained by the (CHI) Cambridge Health Institute.
The Mumbai-Nagpur Expressway, or Samruddhi Mahamarg (officially known as Hindu Hruidaysamrat Balasaheb Thackeray Maharashtra Samruddhi Mahamarg) and Maharashtra Expressway-2 (ME-2), is an existing operational 6-lane wide (expandable to 8), 701-km long access-controlled expressway in the Maharashtra state of India, connecting the Maharashtra's two capital cities, Mumbai in the Marathwada region in the west and Nagpur in the Vidarbha region in the east. By reducing Nagpur-Mumbai travel time to 8 hours, the expressway has boosted the economic development by providing the enhanced connectivity. It is the second expressway in the state of Maharashtra after the Mumbai–Pune Expressway, and the longest within the state.
The first stable human-animal chimeras to actually exist were first created by Shanghai Second Medical University scientists in 2003, the result of having fused human cells with rabbit eggs. In 2017 researchers led by the Salk Institute published in Cell experiments using CRISPR-Cas9 gene editing to aid in blastocyst complementation with pluripotent stem cells in various mammals. This included a human-pig chimera reported to have 0.001% human cells, with the remaining cells pig. The embryo consisted mostly pig cells and some human cells. Scientists stated that they hope to use this technology to address the shortage of donor organs. In 2021, a human-monkey chimera was created as a joint project between the Salk Institute in the US and Kunming University in China and published in the journal Cell. This involved injecting human stem cells into monkey embryos. The embryos were only allowed to grow for a few days, but the study demonstrated that some of these embryos still had human stem cells surviving at the end of the experiments. Because humans are more closely related to monkeys than other animals, it means there is more chance of the chimeric embryos surviving for longer periods so that organs can develop. The project has opened up possibilities into organ transplantation as well as ethical concerns particularly concerning human brain development in primates.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.